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Abstract 
Currently, whether endobronchial ultrasound‑guided transbronchial needle aspiration (EBUS‑TBNA) is superior to 
conventional TBNA (cTBNA) in the diagnosis of mediastinal lymphadenopathy remains controversial. We undertook 
a meta‑analysis of randomized controlled trials (RCTs) to evaluate the diagnostic yield of EBUS‑TBNA versus cTBNA in 
the diagnosis of mediastinal lymphadenopathy, both in benign and malignant etiologies. Computer‑based retrieval 
was performed on PubMed and EMBASE. The quality was evaluated according to the quality assessment of diagnos‑
tic accuracy studies‑2, and Meta‑Disc was adopted to perform meta‑analysis. The pooled sensitivity, specificity, and 
diagnostic odds ratio (DOR) with 95 % confidence intervals (CIs) were calculated. The summary receiving operating 
characteristic curve as well as the areas under curve (AUC) was measured. Four studies with a total of 440 patients 
met the inclusion criteria. Our results showed that the pooled sensitivity was 0.90 (95 % CI 0.85–0.94) and 0.76 (95 % 
CI 0.68–0.82), pooled specificity was 0.75 (95 % CI 0.60–0.87) and 0.94 (95 % CI 0.86–0.98), DOR was 75.38 (95 % CI 
16.38–346.97) and 108.17 (95 % CI 13.84–845.35), and AUC was 0.9339 and 0.9732 for EBUS‑TBNA group and cTBNA 
group, respectively. Although EBUS‑TBNA with a higher sensitivity performs better than cTBNA, there is lack of enough 
evidence regarding EBUS‑TBNA being superior to cTBNA in the diagnosis of mediastinal lymphadenopathy. Consider‑
ing the limitations of methodology and limited data, further robust RCTs are needed to verify the current findings and 
investigate the optimal choice in patients receiving TBNA.
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Background
Mediastinal lymphadenopathy include a variety of benign 
and malignant conditions, such as lung cancer and sar-
coidosis, which are depended on the pathology in terms 
of the gold standard for diagnosis. Hence bronchoscopy 
still plays an important role in the diagnosis of medias-
tinal lymphadenopathy (Zaric et al. 2013). Conventional 
bronchoscopy including mucosal biopsies, brushings, 
lavage cytology, bronchoscopy transmural lung biopsy 
(TBLB), and transbronchial needle aspiration (TBNA), 
can achieve most of the clinical diagnosis for clinicians. 
In the 1980s, Wang et  al. (1983) using a flexible bron-
choscopy firstly improved the TBNA technology includ-
ing the operating needle and ways, which thus promoted 
a widespread application of TBNA. Conventional TBNA 
(cTBNA) is performed to aspirate tissue from thoracic 
masses and pathological lymph nodes through a specially 
designed needle (Wang 1994), which is a well-established 
diagnostic method and widely used in cytological evalu-
ation of thoracic mass lesions. With the development of 
the ultrasound technique, real time endobronchial ultra-
sound-guided (EBUS)-TBNA was introduced into clinical 
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practice by Yasufuku and colleagues in 2004 (Yasufuku 
et al. 2004a, b), which has been widely used in the stag-
ing and diagnosis of mediastinal and hilar lymph node 
(Herth et al. 2006; Varela-Lema et al. 2009; Medford et al. 
2010).
EBUS-TBNA seems to be the optimal choice because 
of real-time visualization, imaging of surrounding ves-
sels and size of the target lesion during the sampling 
procedure (Medford 2011). Several studies showed that 
EBUS-TBNA has high sensitivity, specificity and safety 
in the diagnosis of sarcoidosis and staging of lung can-
cer (Adams et al. 2009; Gu et al. 2009; Varela-Lema et al. 
2009; Yang et al. 2014; Trisolini et al. 2015). In a recent 
overview comparison of different staging modalities 
for non-small cell lung carcinoma, suggested that the 
pooled sensitivity for cTBNA and EBUS-TBNA was 78 
and 89 %, respectively (Vander Laan et al. 2014). How-
ever, other studies suggested that EBUS-TBNA was not 
superior to cTBNA in lung cancer patients with medi-
astinal nodes real-time sampling (Bellinger et  al. 2012; 
Jiang et al. 2014). To our knowledge, the clinical choice 
between EBUS-TBNA and cTBNA in patients with 
mediastinal lymphadenopathy still remains controver-
sial. Furthermore, the diagnostic yield of EBUS-TBNA 
versus cTBNA in mediastinal lymphadenopathy has not 
yet been well established. Therefore, we pre-stated rigor-
ous inclusion criteria and enrolled available randomized 
controlled trials (RCTs) combining EBUS-TBNA and 
cTBNA to critically assess the diagnostic yield of EBUS-
TBNA versus cTBNA in the diagnosis of mediastinal 
lymphadenopathy.
Methods
Search strategy and selection criteria
Computer-based retrieval was performed on PubMed 
and EMBASE (up to Mar 2016) for eligible trials with 
the following keywords: “endobronchial ultrasound” and 
“transbronchial needle aspiration”. Eligible trials limited 
with randomized controlled trial and written in English 
were included. Only published trials were included. Bib-
liographies of all potential studies, including reference 
lists, citation searches, and relevant systematic reviews, 
were manually searched.
The following selection criteria were included: (1) pop-
ulation: consecutive patients (age > 18 years) with medi-
astinal lymphadenopathy undergoing TBNA; (2) study 
design: RCT comparing the diagnostic value of real time 
EBUS-TBNA versus cTBNA in the detection of medi-
astinal lymphadenopathy; (3) sufficient data: reported 
data allowing calculation of the true-positive (TP), false-
positive (FP), false-negative (FN) and true negative (TN) 
values; and (4) reference standard: histopathological and/
or cytological analysis, or close radiological and clinical 
follow up for at least 6 months after TBNA, as the refer-
ence standard.
Data extraction and quality assessment
All data were extracted from all trials by two independent 
investigators (LP and BL). The data included first author, 
publication year, country, number of patients, age and sex 
of patients, needle type, sedation setting, primary results, 
and adverse events. Disagreements among authors were 
settled by discussion or a third investigator (XLC).
The quality of RCTs was evaluated according to the 
quality assessment of diagnostic accuracy studies-2 
(QUADAS-2) (Whiting et al. 2011). The QUADAS-2 tool 
contains four key domains: (1) patient selection, (2) index 
test, (3) reference standard, and (4) flow and timing. Each 
domain is assessed as “yes”, “unclear”, and “no” to judge 
risk of bias. Furthermore, the first 3 domains are also 
assessed as “high”, “Unclear”, and “low” concern to judge 
applicability. We rated the quality assessment and risk of 
bias using the Revman 5.2.0 (Nordic Cochrane Centre).
Statistical analysis
The present study was conducted and reported in accord-
ance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement (Liberati et  al. 
2009). The DerSimonian-Laird random-effects model 
(DerSimonian and Laird 1986; Reitsma et  al. 2005) was 
used to calculate the data as forest plot of pooled sen-
sitivity, specificity, positive likelihood ratio (PLR) and 
negative likelihood ratio (NLP), and diagnostic odds 
ratio (DOR) with 95  % confidence intervals (CIs) for 
EBUS-TBNA and cTBNA, respectively. The summary 
receiving operating characteristic (SROC) curve and the 
pooled diagnostic accuracy (Q* index) as well as the areas 
under curve (AUC) were also measured. The SROC curve 
moves closer to the upper left corner of the larger area 
under the curve, which seems that the accuracy of diag-
nostic tests is higher. Z-test was performed to determine 
whether the sensitivity, specificity, and Q* index of EBUS-
TBNA was significantly different from those of cTBNA. 
Heterogeneity was evaluated using the I2 statistics, and 
threshold effect was determined using the spearman 
correlation coefficient (Higgins and Thompson 2002; 
Higgins et al. 2003). If I2 > 50 %, potential sources of het-
erogeneity were identified by sensitivity analyses, which 
were conducted by omitting one study in each turn and 
investigating the influence of a single study on the overall 
pooled estimate. Furthermore, subgroup analyses were 
performed to explore observed heterogeneity and exam-
ine the influence of various exclusion criteria based on 
sample sizes (>60 vs. ≤60), region (Asia vs. North Amer-
ica), and patients with diagnosis either sarcoidosis or 
other thoracic lesions. All meta-analyses were performed 
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using Meta-DiSc 1.4 (XI Cochrane Colloquium; Barce-
lona, Spain) (Zamora et al. 2006). A two-sided P value of 
<0.05 was regarded as indicate statistical significance.
Results
Bibliographic search results
A total of 1160 relevant articles were identified from the 
initial search. After reviewing the titles and abstracts, 
1155 were excluded for duplicate studies and various 
reasons (e.g., case reports, editorials, reviews, non-rand-
omized control trials, and or not using both EBUS-TBNA 
and cTBNA). A detailed flowchart for the study selec-
tion is presented in Fig. 1. Finally, the remaining 4 eligi-
ble RCTs with a total of 440 patients were identified for 
the present meta-analysis (Arslan et al. 2011; Gupta et al. 
2014; Tremblay et al. 2009; Herth et al. 2004).
Baseline characteristics and quality assessment
The main characteristics of the retrieved RCTs are shown 
in Table 1. From Table 1, we found that the sample size 
of 4 trials ranged from 50 to 200 and these RCTs were 
published between 2004 and 2014. Four RCTs involv-
ing 440 patients were conducted in 4 countries includ-
ing Turkey (Arslan et al. 2011), India (Gupta et al. 2014), 
American (Herth et  al. 2004), and Canada (Tremblay 
et  al. 2009). Two RCTs enrolled patients with clinical 
diagnosis or suspected of sarcoidosis that had enlarged 
lymph nodes >1  cm (Tremblay et  al. 2009; Gupta et  al. 
2014), and patients with other thoracic lesions that had 
at least one mediastinal node ≥0.7 (Herth et al. 2004) and 
2 cm (Arslan et al. 2011) in short-axis diameter on com-
puted tomography were included in the remaining two 
RCTs. Furthermore, all bronchoscopies were performed 
by experienced pulmonologists or by fellows under direct 
supervision. No rapid on-site evaluation (ROSE) was 
used in 4 RCTs. Additionally, the type of sedation was 
not the same settings in the four RCTs.
Two authors (LP and BL) agreed on each item of the 
QUADAS-2. The risk-of-bias analyses suggested that all 
trials were followed at low risk in terms of patient selec-
tion, index test, reference standard, and flow and timing 
except only one RCT (Gupta et al. 2014) with a high risk 
of the index test. In addition, all trials were followed in 
high concern regarding applicability. The detailed quality 
assessment of 4 RCTs was illustrated in Fig. 2.
Diagnostic value of EBUS‑TBNA and cTBNA
The overall diagnostic sensitivity was 0.91 (95 % CI 0.85–
0.94; χ2 =  32.36; I2 =  90.7  %) and 0.76 (95  % CI 0.68–
0.82; χ2 = 61.49; I2 = 95.1 %), specificity was 0.92 (95 % 
Fig. 1 PRISMA flow diagram. RCT randomized controlled trial
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CI 0.78–0.98; χ2 = 6.61; I2 = 54.6 %) and 0.94 (95 % CI 
0.86–0.98; χ2 = 1.92; I2 = 0.0 %) for EBUS-TBNA group 
(Fig. 3) and cTBNA group (Fig. 4), respectively. Hetero-
geneity was significant in terms of the pooled sensitivity 
for two arms. Next, sensitivity analyses were performed 
to further explore potential source of heterogeneity 
across studies. Further exclusion of any single study 
did not resolve the heterogeneity, and the pooled sen-
sitivity ranged from 0.82 (95 % CI 0.73–0.89; χ2 =  9.05; 
I2  =  77.9  %) to 0.97 (95  % CI 0.93–0.99; χ2  =  10.09; 
I2  =  80.2  %), 0.59 (95  % CI 0.48–0.69; χ2  =  14.12; 
I2  =  85.8  %) to 0.95 (95  % CI 0.88–0.98; χ2  =  16.83; 
I2 = 88.1 %) for EBUS-TBNA group and cTBNA group, 
respectively. Moreover, threshold effect analysis showed 
that their spearman correlation coefficients were respec-
tively 0.949 (P = 0.051) and 0.400 (P = 0.600) for EBUS-
TBNA group and cTBNA group, which suggested that no 
diagnostic threshold effect existed for histological diag-
noses, and we believe that the heterogeneity among stud-
ies could mainly result from clinical and methodological 
differences.
The pooled PLR, NLR, and DOR were 3.19 (95  % CI 
2.03–5.00), 0.09 (95  % CI 0.01–0.67), and 75.38 (95  % 
CI 16.38–346.97) for EBUS-TBNA group, respectively. 
Correspondingly, the pooled PLR, NLR, and DOR were 
11.11 (95  % CI 5.16–23.96), 0.11 (95  % CI 0.01–1.47), 
and 108.17 (95  % CI 13.84–845.35) for cTBNA group, 
respectively. Additionally, the two SROC were presented 
Fig. 2 Study quality assessment by the quality assessment of diagnostic accuracy studies‑2 criteria: a Risk of bias and applicability concerns sum‑
mary: review authors’ judgements about each domain for each included study; b Risk of bias and applicability concerns graph: review authors’ 
judgements about each domain presented as percentages across included studies
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Fig. 3 Forest plots of the pooled sensitivity and specificity for EBUS‑TBNA by the random‑effects model
Fig. 4 Forest plots of the pooled sensitivity and specificity for cTBNA by the random‑effects model
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in Fig.  4, which showed that AUC and Q* index with a 
standard error (SE) were 0.9339 (0.8698  ±  0.0526) and 
0.9732 (0.9252 ± 0.0275) for EBUS-TBNA group (Fig. 5a) 
and cTBNA group (Fig. 5b), respectively.
Specifically, the Z-test results suggested that the pooled 
sensitivity of EBUS-TBNA was significantly higher than 
that of cTBNA (P  <  0.01), and the pooled specificity, 
Fig. 5 Summary receiving operating characteristic curve and Q* index for EBUS‑TBNA (a) and cTBNA (b)
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DOR and Q* index of cTBNA were obviously higher than 
those of EBUS-TBNA (all P < 0.01).
Subgroup analyses
Also, we performed subgroup analyses using a random 
effects model to explore the heterogeneity of sensitiv-
ity and examine the influence of various exclusion crite-
ria based on sample sizes (>60 vs. ≤60), region (Asia vs. 
North America), and patients with diagnosis either sar-
coidosis or other thoracic lesions. Table  2 showed the 
detailed indication for subgroup analyses of EBUS-TBNA 
and cTBNA for the pooled sensitivity, specificity and 
DOR in all eligible studies.
Safety
From Table  1, we found that there were no obvious 
complications observed in two groups excluding rare 
patients with minor or moderate bleeding. Both EBUS-
TBNA and cTBNA are safe and provide a well tolerated 
approach in the diagnosis of patients with mediastinal 
lymphadenopathy.
Discussion
The current meta-analysis including 4 RCTs was con-
ducted to critically evaluate the diagnostic value of 
EBUS-TBNA compared with cTBNA in patients with 
mediastinal lymphadenopathy. The results of our study 
indicated that both EBUS-TBNA and cTBNA are safe and 
provide good diagnostic value for patients with mediasti-
nal lymphadenopathy. EBUS-TBNA with a higher sensi-
tivity performs better than cTBNA, however, the pooled 
specificity, DOR and Q* index of cTBNA were obviously 
higher than those of EBUS-TBNA.
EBUS-TBNA has been a new approach in the estima-
tion of thoracic disease not only in nonmalignant dis-
eases such as sarcoidosis and tuberculosis but also in 
mediastinal lymphadenopathy, particularly in cases of 
malignancy (Garwood et  al. 2007; Tournoy et  al. 2010; 
Schmid-Bindert et al. 2013; Lee et al. 2014). Up to now, 
the latest guideline and expert panel report about the 
technical aspects of EBUS-TBNA was published on 
CHEST (Wahidi et al. 2015). The authors recommended 
that EBUS-TBNA be used for diagnosis in patients with 
suspected sarcoidosis, tuberculosis and even lymphoma. 
However, as well as the previous systematic reviews 
(Adams et  al. 2009; Gu et  al. 2009; Varela-Lema et  al. 
2009; Yang et  al. 2014; Trisolini et  al. 2015), they had a 
common point that they did not compare EBUS-TBNA 
with cTBNA. Additionally, even if they enrolled some 
trials combining EBUS-TBNA and cTBNA arms, these 
trials were non-RCT, such as retrospective or obser-
vational studies. Importantly, conclusions in terms of 
diagnostic yield cannot be drawn until further head-to-
head evidence is available. Therefore, different from the 
aforementioned systematic reviews, we enrolled avail-
able RCTs combining EBUS-TBNA and cTBNA to criti-
cally assess the diagnostic value of EBUS-TBNA versus 
cTBNA in patients with mediastinal lymphadenopathy.
In the present meta-analysis, we mainly focused on 
evaluating the diagnostic value across EBUS-TBNA and 
cTBNA arms during the diagnosis of mediastinal lym-
phadenopathy, both in benign and malignant etiologies. 
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Our results showed that the pooled sensitivity was 0.90 
and 0.76, specificity was 0.75 and 0.94, DOR was 75.38 
and 108.17, and AUC was 0.9339 and 0.9732 for EBUS-
TBNA group and cTBNA group, respectively. Moreover, 
the Z-test results suggested that the pooled sensitiv-
ity of EBUS-TBNA was considerably higher than that of 
cTBNA, and the pooled specificity, DOR and Q* index 
of cTBNA were obviously higher than those of EBUS-
TBNA. Based on the above results, we believed that our 
results could not be used as the basis to choose the oper-
ating mode of TBNA for the clinicians, and the choice 
needs to be followed the principle of individuation. Next, 
in the present study, sensitivity analyses did not obviously 
alter the heterogeneity among studies for the pooled sen-
sitivity. The results from subgroup analyses indicated that 
EBUS-TBNA might be superior to cTBNA in patients 
from Asia and with diagnosis or suspected of sarcoido-
sis in terms of the pooled sensitivity. But further studies 
are needed to investigate these topics. Finally, threshold 
effect analysis showed that no diagnostic threshold effect 
existed for histological diagnoses, which indicated that 
the heterogeneity among studies could be seen as a result 
of clinical and methodological differences.
Additional areas of study are important for future clini-
cal research. Advanced technology and equipment means 
more expense; therefore, cost-effective analyses are 
needed. Moreover, further segregation of the diagnostic 
yield in malignant versus benign disease is needed as it 
is difficult to delineate which approach is more effective 
for various patients (Yarmus et al. 2011; Jiang et al. 2014). 
This is especially true of lung cancer staging as there is 
no comparison of these two modalities with regard to 
accurately staging the mediastinum in patients with non 
small cell lung cancer. Therefore, future research should 
pay more attention to the tailoring principle of individu-
ation. Additionally, performance experience and learn-
ing curve are considerable factors. While EBUS-TBNA 
may seem to be a more secure, attractive and dependable 
modality to the inexperienced bronchoscopist (Yarmus 
et al. 2011), the learning curves for both modalities were 
reported (Bellinger et al. 2014; Haponik et al. 1995; Her-
mens et al. 2008; Kemp et al. 2010; Mehta 2013; Wahidi 
et al. 2014). Next, the type of sedation was not the same 
settings in the four RCTs. Does less sedation for cTBNA 
make it more cost effective? Future research should 
focus on the important issue. Finally, cTBNA combin-
ing ROSE has been proven to have many benefits, such 
as improving the diagnostic yield, decreasing the number 
of needle passes, and reducing the need for additional 
diagnostic procedures (Diacon et al. 2005; Mondoni et al. 
2013; Gasparini and Bonifazi 2014). However, ROSE was 
not used in the four RCT analyzed in our study, and it 
is unknown if the addition of ROSE would affect yield in 
a comparative study of these modalities. Further trials 
are warranted to compare the role of EBUS-TBNA with 
ROSE versus that of cTBNA with ROSE.
To be sure, several limitations exist in our study. First, 
the patients were heterogenous with a mixture of benign 
and malignant etiologies, and different size a location of 
the intrathoracic or mediastinal lymph nodes. Second, 
procedural aspects were also heterogenous, such as the 
number of aspiration passes, the type of needle, and the 
type of sedation. Operator experience level is variable 
which may affect the applicability of our results. Third, 
four RCTs with a wide variation in sample size were 
incorporated into our analysis. Overestimation of the 
diagnostic value is the most likely to occur in smaller 
than in larger studies. Finally, several unpublished or 
missing data may increase the risk of bias.
Conclusions
In summary, this study suggests that both EBUS-TBNA 
and cTBNA are safe and provide diagnostic value for 
mediastinal and hilar adenopathy. Both have advantages 
and disadvantages. The optimal choice of procedure 
should be individualized based on availability, patient 
characteristics and operator experience. Further robustly 
designed RCTs are needed to better explore the current 
findings and continue to investigate the most appropriate 
diagnostic modality.
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